Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial
Start your intake What Long-Term Clinical Trials Reveal About Semaglutide Safety The STEP trials, which tracked semaglutide use for up to 68 weeks, found that gastrointestinal side effects like nausea peaked during the first 4-8 weeks and declined substantially by month 3 in most participants
This case study elucidates our methodological approach and expertise in successfully executing peptide sequencing of Semaglutide for a clients late-stage filing. Learn more about our end-to-end peptide sequencing capabilities through our dedicated Peptide Sequencing Service : Key Highlights Demonstrates how comprehensive peptide sequencing enables batch consistency, biosimilar comparability, and successful regulatory filing
) successfully identified multiple insulinomas in confirmed MEN-1 patients with the tracer 68Ga-NOTA-exendin-4 PET/CT imaging
Each boxplot shows medians, interquartile ranges (IQR), and outliers